Illumina Inc ILMN

NAS: ILMN | ISIN: US4523271090   26/12/2025
134,95 USD (-0,27%)
(-0,27%)   26/12/2025

16 december 2025 · Illumina To Webcast Upcoming Investor Conference · Persbericht

14 december 2025 · /C O R R E C T I O N -- MyOme, Inc/ · Persbericht

11 december 2025 · Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually · Persbericht

12 november 2025 · Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study · Persbericht

11 november 2025 · Illumina To Webcast Upcoming Investor Conference · Persbericht

10 november 2025 · Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks · Persbericht

5 november 2025 · Illumina Responds to Positive Updates from Chinese Ministry of Commerce · Persbericht

30 oktober 2025 · Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 · Persbericht

15 oktober 2025 · Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights · Persbericht

15 oktober 2025 · Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot · Persbericht

14 oktober 2025 · Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025 · Persbericht

1 oktober 2025 · Illumina launches new business to accelerate technology and data-driven discovery · Persbericht

23 september 2025 · Illumina advances personalized cancer care with new pharma development partnerships · Persbericht

23 september 2025 · Vooruitblik op Amerika · Bolero.be

Voor de bel Amerikaanse futures en beursopening Op basis van de futures wordt een licht hogere opening voor de Amerikaanse aandelenmarkt voorspeld, na een technologiegedreven rally die de belangrijkste indexen voor de derde...

18 september 2025 · Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine · Persbericht

8 september 2025 · Lancement d'Illumina® Protein Prep pour améliorer les connaissances protéomiques et faciliter les découvertes et le développement de médicaments · Persbericht

3 september 2025 · Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development · Persbericht

31 juli 2025 · Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 · Persbericht

30 juli 2025 · Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling · Persbericht

10 juli 2025 · Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025 · Persbericht

Mijn selecties